Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for ESS40005

Result Summary for ESS40005

Result Summary

Protocol ID:	ESS40005
Clinical Study ID:	ESS40005
Official Title:	A Phase IIIB Randomized, Multi-center Study of the Efficacy and Safety of COMBIVIR 1 Tablet PO BID Plus ZIAGEN 300mg PO BID Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet PO BID, Administered for 24 Weeks in Subjects With HIV-1 Infection
Phase:	Phase 3
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	trizivir;trizivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	M. Fischl, A. Burnside, C. Farthing, M. Thompson, N. Bellos, V. Williams, and M. Shaefer Efficacy of Combivir (COM) (Lamivudine 150mg/ Zidovudine 300mg) plus Ziagen (Abacavir (ABC) 300mg) BID Compared to Trizivir (TZV) (3TC 150mg/ZDV 300mg/ABC 300mg) BID in Patients Receiving Prior COM plus ABC (Poster 315) 8th Conference on Retroviruses and Opportunistic Infections Margaret A. Fischl, M.D., Alfred F. Burnside, Jr., M.D., Charles E. Farthing, M.D., Melanie A. Thompson, M.D., Nicholaos C. Bellos, M.D., Vanessa C. Williams, M.S., Teresa L. Kauf, Ph.D., Paul G. Wannamaker, B.A., Mark S. Shaefer, Pharm.D. Twice-Daily Trizivir Versus Combivir-Abacavir in Antiretroviral-Experienced Adults with Human Immunodeficiency Virus-1 Infection: A Formulation Switch Trial. Pharmacotherapy. 2003;23(11):1432-1440.